Kyverna Therapeutics (NASDAQ:KYTX) Announces Earnings Results

Kyverna Therapeutics (NASDAQ:KYTX) issued its quarterly earnings data on Thursday. The company reported ($0.68) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.68), FiscalAI reports.

Kyverna Therapeutics Stock Performance

Shares of NASDAQ KYTX traded down $0.09 during trading on Thursday, reaching $5.03. The stock had a trading volume of 1,198,533 shares, compared to its average volume of 806,677. Kyverna Therapeutics has a one year low of $4.49 and a one year high of $13.67. The company has a debt-to-equity ratio of 0.15, a current ratio of 9.06 and a quick ratio of 9.06. The firm’s 50 day moving average price is $6.28 and its two-hundred day moving average price is $7.90.

Analysts Set New Price Targets

A number of equities analysts have issued reports on KYTX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Monday, September 21st. HC Wainwright reissued a “buy” rating on shares of Kyverna Therapeutics in a research report on Thursday, October 22nd. Benchmark restated a “buy” rating on shares of Kyverna Therapeutics in a research note on Friday, September 25th. William Blair raised shares of Kyverna Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. Finally, Needham & Company LLC set a $25.00 price target on shares of Kyverna Therapeutics in a research report on Friday, September 25th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $29.00.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for people with autoimmune diseases. The company’s approach aims to use engineered immune cells to address disease-causing B cells. Its lead candidate, KYV-101, is an autologous CAR T-cell therapy designed to target CD19, a protein found on B cells. Kyverna is evaluating the therapy in clinical studies for several autoimmune conditions, including stiff person syndrome, myasthenia gravis and lupus nephritis.